Dr. Dina Radenkovic, M.B.B.S, is a physician-turned-entrepreneur and the Co-founder and CEO of Gameto, a biotechnology company pioneering cell engineering solutions in women’s and family health. Under her leadership, Gameto has raised $127 million to date, including a $10 million award from ARPA-H, with support from investors such as Two Sigma Ventures, RA Capital, Future Ventures, Insight Partners, Bold Capital, Lux Capital, Ingeborg Investments, Bob Nelson of Arch Ventures, and Anne Wojcicki of 23andMe.
Gameto’s lead program, Fertilo, is the first iPSC-derived therapeutic to reach Phase 3 in the United States. Fertilo aims to make IVF and egg freezing shorter, safer, and more accessible by enabling eggs to mature outside the body, reducing the burden of hormonal injections. The program is actively recruiting patients across more than 12 clinical sites in the U.S., has already received ex-U.S. regulatory approvals, and has resulted in the birth of six healthy babies to date.
Beyond fertility, Gameto is advancing a pipeline in women’s health, including a program addressing menopause, leveraging its proprietary iPSC-derived cell engineering platform developed in collaboration with Professor George Church’s lab at Harvard Medical School.
Dr. Radenkovic earned her dual degree in medicine and physiology from UCL Medical School, London, and completed her residency at St Thomas’ Hospital in London. She has held research posts at King’s College London and the Buck Institute for Research on Aging, and was previously a partner at SALT Bio Fund, investing in early- and mid-stage life sciences companies.